Medpace (NASDAQ:MEDP) Stock Price Up 1.1%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price shot up 1.1% on Friday . The company traded as high as $395.98 and last traded at $394.83. 14,238 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 237,573 shares. The stock had previously closed at $390.58.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MEDP. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Robert W. Baird increased their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Guggenheim increased their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and increased their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Trading Up 0.6 %

The business’s fifty day simple moving average is $395.45 and its 200 day simple moving average is $344.78. The stock has a market cap of $12.18 billion, a P/E ratio of 40.25, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.27 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO August J. Troendle sold 4,782 shares of Medpace stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the transaction, the chief executive officer now owns 716,197 shares of the company’s stock, valued at approximately $286,894,194.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Medpace news, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total transaction of $1,915,573.56. Following the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at approximately $286,894,194.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ashley M. Keating sold 250 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at $102,467.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 145,236 shares of company stock valued at $59,626,117. 20.30% of the stock is currently owned by insiders.

Institutional Trading of Medpace

Hedge funds have recently bought and sold shares of the stock. RiverPark Advisors LLC acquired a new stake in Medpace during the 4th quarter worth approximately $26,000. Contravisory Investment Management Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $26,000. Rise Advisors LLC acquired a new stake in shares of Medpace in the first quarter valued at approximately $27,000. Mather Group LLC. acquired a new stake in shares of Medpace in the first quarter valued at approximately $28,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.